Psoriasis is a chronic, immune-mediated skin disorder characterized by red, scaly patches that can cause itching, discomfort, and emotional distress. It affects around 2–3 % of the global population and, in severe cases, can extend beyond the skin to involve the joints, leading to psoriatic arthritis. Beyond its visible symptoms, psoriasis is associated with systemic inflammation and other health issues such as cardiovascular disease, diabetes, and depression.
Access insight on Psoriasis Market
At its core, psoriasis occurs due to an overactive immune system that triggers excessive production of skin cells. The imbalance of immune signaling molecules, particularly cytokines like tumor necrosis factor-alpha (TNF-?), interleukin-17 (IL-17), and interleukin-23 (IL-23), plays a key role in sustaining the inflammatory cycle.
For decades, treatment relied on topical corticosteroids, phototherapy, or systemic drugs like methotrexate and cyclosporine. While these helped manage symptoms, they often came with side effects and limited long-term control. The growing understanding of immune pathways has paved the way for biologics and, more recently, biosimilars — therapies that are transforming psoriasis management.
Don’t Miss Out on the Next Wave of Psoriasis Therapies – Book a preview
Biologic therapies are advanced medications derived from living cells. They use cutting-edge biotechnology to create monoclonal antibodies that block inflammatory molecules responsible for psoriasis flare-ups.
The main types of biologics for psoriasis include:
• TNF inhibitors (e.g., adalimumab, etanercept, infliximab)
• IL-12/23 inhibitors (e.g., ustekinumab)
• IL-17 inhibitors (e.g., secukinumab, ixekizumab)
• IL-23 inhibitors (e.g., guselkumab, risankizumab, tildrakizumab)
These drugs have revolutionized treatment, helping patients achieve PASI-90 or PASI-100 clearance near-complete elimination of skin lesions.
Biosimilars are highly similar versions of already approved biologic drugs. They have the same mechanism of action, route of administration, and clinical efficacy as their reference biologics but are typically 30–50% more affordable.
Unlike generic drugs, biosimilars are not exact chemical copies they’re complex biological products that undergo extensive testing to prove equivalent safety, purity, and potency.
The emergence of biosimilars has made advanced psoriasis treatments more accessible, especially in developing regions where biologics were previously unaffordable.
Download the complete TOC now!
Modern biologics have set new benchmarks in psoriasis treatment, offering long-term disease remission rather than temporary symptom relief. With precise targeting of IL-17 and IL-23 pathways, patients now experience higher rates of sustained clearance and better control over flare-ups.
The introduction of biosimilars has triggered competitive pricing in the biologics market. As patents of major biologics such as Humira and Stelara expire, biosimilar versions are entering the market at lower costs, improving accessibility. This is particularly significant for developing nations, where treatment affordability has long been a barrier to care.
Lower prices and growing regulatory approvals are driving biologic and biosimilar adoption in emerging markets across Asia-Pacific, Latin America, and Eastern Europe. This expansion is helping bridge treatment gaps and ensuring more equitable healthcare access for patients worldwide.
The success of biosimilars is pushing pharmaceutical companies to innovate further. New biologics with longer dosing intervals, improved delivery systems, and novel targets are entering the pipeline. Some companies are also exploring dual-acting biologics and advanced immunotherapies, signaling a new phase of therapeutic sophistication.
Studies show that switching from an originator biologic to a biosimilar can be done safely and effectively in many cases. This flexibility allows healthcare systems to optimize costs without compromising patient outcomes, paving the way for more sustainable healthcare models.
Innovative biologics have redefined what’s possible in psoriasis treatment, turning once-debilitating conditions into manageable chronic diseases. Biosimilars are now amplifying that impact by making high-quality therapies accessible to a broader population.
Together, they are reshaping the global psoriasis treatment landscape — driving a future where innovation and affordability coexist. As more countries embrace biosimilars and invest in biologic innovation, patients around the world can look forward to a new era of personalized, equitable, and effective psoriasis care.
